MAP2K7 and neuroblastoma: Coggins showed that the MEK inhibitor trametinib induces YAP nuclear translocation while reducing cytoplasmic YAP in RAS- or NF1-mutated neuroblastoma cell lines, suggesting resistance to MEK inhibitor therapy via YAP activation [52].